AUG 7·SEC EDGARLow
Britt Lisa P. sold $3.4M of TMO
Britt Lisa P. (Sr. VP and Chief HR Officer) sold 5,850 shares of THERMO FISHER SCIENTIFIC INC. (TMO) at $580.00 ($3.39M total) on 2026-08-06.
StockNYSE · US · USDHealthcare · Diagnostics & Research
$TMO
THERMO FISHER SCIENTIFIC INC.
Price · $TMOvia TradingView
AI sentiment · 7d4 articles
- Bullish
- 3
- Neutral
- 0
- Bearish
- 1
Top stories · $TMOMore →
AUG 7·SEC EDGAR
CASPER MARC N sold $2.9M of TMO (indirect holdings)
CASPER MARC N (Chairman & CEO) sold 5,000 indirectly-held shares of THERMO FISHER SCIENTIFIC INC. (TMO) at an average of $574.45 ($571.00–$580.01, $2.87M total) across 9 trades on 2026-08-06 under a Rule 10b5-1 trading plan.
AUG 7·SEC EDGAR
CASPER MARC N sold $5.7M of TMO
CASPER MARC N (Chairman & CEO) sold 10,000 shares of THERMO FISHER SCIENTIFIC INC. (TMO) at an average of $574.47 ($571.05–$579.90, $5.74M total) across 9 trades on 2026-08-06 under a Rule 10b5-1 trading plan.
TMO sentiment & insider activity
Over the past 7 days, alphai's AI scored 4 news stories mentioning TMO (THERMO FISHER SCIENTIFIC INC.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 1 bearish.
Recent TMO coverage spans insider activity, earnings and technology.
In the last 30 days, TMO insiders filed 42 SEC Form 4 transactions — no purchases and 42 sales ($20.9M). The most active reporter was CASPER MARC N, Chairman & CEO, with 40 filings. 98% of activity was filed under pre-arranged Rule 10b5-1 plans.
What's driving TMO
A routine Form 4 open-market sale by a senior HR officer, with no 10b5-1 plan cited, may slightly affect sentiment but is not a fundamental catalyst.
This is a routine insider sale under a pre-arranged 10b5-1 plan, so it is more of a positioning signal than a fundamental catalyst.
Insider selling is disclosed via Form 4, but it is pre-arranged under a 10b5-1 plan, reducing signal strength.
This is a routine insider sale under a pre-arranged 10b5-1 plan, so it is more of a sentiment signal than a fundamental catalyst.
Insider selling is a near-term sentiment signal, but the disclosed 10b5-1 plan reduces the likelihood of immediate fundamental information.
alphai scores every news story that mentions TMO with an AI model for sentiment and relevance, and aggregates insider trades from THERMO FISHER SCIENTIFIC INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $TMO
Score
Britt Lisa P. sold $3.4M of TMO
Britt Lisa P. (Sr. VP and Chief HR Officer) sold 5,850 shares of THERMO FISHER SCIENTIFIC INC. (TMO) at $580.00 ($3.39M total) on 2026-08-06.
2 min readCASPER MARC N sold $2.9M of TMO (indirect holdings)
CASPER MARC N (Chairman & CEO) sold 5,000 indirectly-held shares of THERMO FISHER SCIENTIFIC INC. (TMO) at an average of $574.45 ($571.00–$580.01, $2.87M total) across 9 trades on 2026-08-06 under a Rule 10b5-1 trading plan.
2 min readCASPER MARC N sold $5.7M of TMO
CASPER MARC N (Chairman & CEO) sold 10,000 shares of THERMO FISHER SCIENTIFIC INC. (TMO) at an average of $574.47 ($571.05–$579.90, $5.74M total) across 9 trades on 2026-08-06 under a Rule 10b5-1 trading plan.
2 min readCASPER MARC N sold $2.9M of TMO (indirect holdings)
CASPER MARC N (Chairman & CEO) sold 5,000 indirectly-held shares of THERMO FISHER SCIENTIFIC INC. (TMO) at an average of $575.23 ($566.26–$577.56, $2.88M total) across 11 trades on 2026-08-05 under a Rule 10b5-1 trading plan.
2 min readCASPER MARC N sold $5.8M of TMO
CASPER MARC N (Chairman & CEO) sold 10,000 shares of THERMO FISHER SCIENTIFIC INC. (TMO) at an average of $575.23 ($566.25–$577.56, $5.75M total) across 11 trades on 2026-08-05 under a Rule 10b5-1 trading plan.
2 min read
Thermo Fisher Stock Clawed Back From a 31% Slide. A Guidance Raise May Explain Why.
Thermo Fisher Scientific (TMO) reported 5% organic revenue growth in Q2, ahead of prior guidance, and raised full-year adjusted EPS guidance to $24.93 to $25.33 on its July 23, 2026 earnings call. The article cites broad-based demand strength across pharma, biotech, academic and government, and notes TMO analysts remain mostly bullish.
4 min readWill Thermo Fisher's (TMO) New EXENT Myeloma Platform and Q2 Results Shift Its Diagnostics Narrative?
Thermo Fisher Scientific (TMO) said it showcased diagnostic launches and FDA clearances at the ADLM conference, including its EXENT multiple myeloma platform and EliA CTD 13 autoimmune assay. The company reported Q2 2026 sales of $11.99B and net income of $1.74B, and discussed longer-term revenue and earnings projections to 2029.
6 min read
Charlotte Area Reports 1,622 Job Cuts Through July as Layoffs Rise 10% From 2025
WARN notices filed with North Carolina’s Department of Commerce show 1,622 job cuts in the Charlotte area through July 2026, up 10% from the same period in 2025. Statewide cuts exceed 5,310, up 38% year over year. Notable actions include Family Dollar closing a Matthews distribution center (373 jobs) and Thermo Fisher eliminating 423 roles in Buncombe County.
4 min readThermo Fisher (TMO) Wins Two FDA Clearances As It Unveils New Diagnostics
Thermo Fisher Scientific (TMO) reported FDA 510(k) clearances for its EXENT Solution for multiple myeloma diagnosis and EliA CTD 13 Screen for systemic autoimmune connective tissue diseases, announced at the 2026 AACC meeting. It also highlighted previously cleared oncology and preeclampsia assays and new digital lab workflow tools. Shares trade near $574.3.
3 min read
Analysts Appear Bullish on Thermo Fisher (TMO): Is The Stock Really a Buy After Earnings?
Thermo Fisher Scientific (TMO) reported fiscal Q2 2026 results. Revenue rose 10% to $11.99B, GAAP diluted EPS rose 9% to $4.68, and adjusted EPS rose 13% to $6.03, with adjusted operating margin at 22.8%. Analysts including RBC raised price targets, and management raised full-year revenue guidance to $47.4B-$48.1B.
6 min read